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1. Introduction 
There are numerous trials in hypertension many of which have focused on cardiovascular 
(CV) outcomes (death, non–fatal Myocardial Infarction, stroke, congestive heart failure). 
These trials have influenced our clinical practice in terms of setting out guidelines in the 
treatment of Hypertension. However, the last three years have seen newer trials emerge 
which we feel will influence the new upcoming guidelines. 
 Making sense of these trials and applying their conclusions into clinical practice remains a 
formidable challenge to physicians. In this chapter we will not only review landmark trials, 
but also attempt to analyse them and suggest recommendations to be applied in daily 
practice. The trials will be evaluated according to the following three major categories:  
1. Trials in Patients with Essential Hypertension (Hypertension Trials) 
2. Trials in patients with renal disease and renal outcomes (Renal Trials) 
a. Non-Diabetic   
b. Diabetic 
3. Trials in patients with high cardiovascular risk and focusing on cardiovascular 
outcomes. (Cardiovascular Trials) 
2. Hypertension trials 
All physicians are faced with the dilemma of which drug is the best choice for patients 
with essential hypertension. By best choice we mean, the drug that is most economical, 
has a high safety profile and improves cardiovascular mortality. Our drug choice has been 
influenced over time by various published trials that will be reviewed. However, it is 
important to start first by evaluating a trial looking at lifestyle modification in essential 
hypertension. 
TOHP Trial (Trial of Hypertension Prevention) (1) and its long-term follow-up TOHP-2(2) 
were the main studies on lifestyle modification. This randomized, placebo controlled trial of 
2812 patients demonstrated that weight loss is the most effective lifestyle modification, 
reducing SBP and DBP on average by 2.9/2.3 mm Hg for every 4 kilogram weight loss. 
Dietary sodium restriction reduced BP by 2/1 mm Hg for every 44-meq/ day decreasing 
salt intake. All other arms, reductions in calcium or magnesium, fish oil and stress 
management failed to achieve sustained blood pressure improvement. Though non-
pharmacologic measures lead to modest BP effects, it nevertheless has great clinical 
significance. This was also shown in large trials such as ALLHAT and VALUE, where even 
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small differences of -4/-3 mm Hg were associated with significant reduction in stroke (23%), 
coronary heart disease (15%) and mortality (14%). 
As monotherapy most of the drugs produce effective response in about 30 percent of cases 
(3,4). However there is wide inter-patient and inter-racial variability. Black patients for 
instance, respond better to CCBs and diuretics, whereas white patients have better response 
to ACE/ARBs and Beta-blockers. This variability may be related to low renin-high volume 
conditions in the former and high renin-low volume in the latter. Hence results of individual 
trials are not generalizable and apply only to the specific study population. 
TOMHS Trial (Treatment of Mild Hypertension Study) attempted to evaluate the 
response of 5 major first line drugs in a predominant white population (5). The efficacy of 
the drugs was essentially similar although the CCB group (Amlodipine) had the highest 
percentage of patients responding to monotherapy. 
ALLHAT Trial (Antihypertensive and Lipid Lowering to prevent Heart Attack Trial) is a 
randomised prospective trial of 45,000 patients with hypertension and one additional risk 
factor for coronary heart disease (6).  ALLHAT compared primary (fatal coronary heart 
disease and non fatal myocardial infarction) and secondary (congestive heart failure, stroke 
etc.) cardiovascular outcomes among those randomly assigned chlorthalidone (12.5-25 
mg/day) to one of three other arms: CCB (Amlodipine), ACEI (Lisinopril) and alpha 
adregenic blocker (Doxazosin). The initial mean untreated and treated blood pressures were 
similar (156/89 and 145/83). The Doxazosin arm was prematurely terminated due to 
increased risk of heart failure compared to diuretics. It should be noted that though the 
Doxazosin arm was stopped in February 2000, the primary end point, reduction in 
cardiovascular mortality from myocardial infarction was not different between two groups. 
This occurred despite the thiazide diuretic groups having a SBP 3 mm Hg lower than the 
alpha-blocker group. 
The incidence of primary outcome (fatal coronary heart disease and non fatal myocardial 
infarction) was similar for all three agents. The CCB arm compared to diuretic had a higher 
rate of heart failure but other secondary outcomes were similar. The ACEI arm compared to 
diuretic had higher combined cardiovascular outcomes, stroke and heart failure. Blacks and 
non-diabetics in the ACEI arm had higher rates of these unfavourable outcomes. The higher 
risk of heart failure seen with Amlodipine and Lisinopril was greatest in the first year. This 
was attributed mainly to better blood pressure control in the diuretic arm. The risk was 
greatly attenuated after the first year when blood pressures were similar. The mean increase 
in fasting glucose in non-diabetics was higher in diuretic arm versus ACEI or CCB. The 
ALLHAT Trial showed that in patients with hypertension and high risk for cardiovascular 
disease, diuretics (chlorthalidone), CCB (Amlodipine) and ACEI (Lisinopril) had same 
protection from fatal coronary heart disease and nonfatal myocardial infarction. Amlodipine 
was not associated with excessive cardiac deaths as suggested by INSIGHT trial though the 
higher rate of congestive heart failure is consistent with other trials (7). 
ANBP2 Trial (Second Australian National Blood Pressure) compared an ACEI (Lisinopril) 
with diuretic (Hydrochlorothiazide) in elderly hypertensive patients (8). The ANBP2 trial 
was a prospective trial of 6000 participants. The primary outcome was all cardiovascular 
events. These included coronary events (myocardial infarction, sudden death from cardiac 
events), cardiovascular events (heart failure, vascular cause of death) and cerebrovascular 
(stroke or transient ischemic episode). At the end of the study both arms had similar 
reductions of blood pressure of 26/12 mm Hg. Approximately 65 percent of patients in both 
arms needed monotherapy while the rest needed two or more agents. The ACEI arm had 
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better cardiovascular outcomes as compared to the diuretic arm. While fatal events were the 
same in both arms, the incidence of non-fatal cardiovascular events was less in the ACEI 
arm. This was in contradiction to the ALLHAT trial that showed that diuretics were more 
effective in cardiovascular outcomes. 
Stop-Hypertension 2 Trial comparing ACEI (Lisinopril) vs. dihydropyridine CCB (DHP-
CCB) in this case Felodipine or Isradipinevs. Beta-blocker and /or diuretic, found no 
difference in cardiovascular end points (9). NORDIL Trial (Nordic Diltiazem Trial) 
comparing CCB (Diltiazem) combined with either a diuretic or Beta-blockers or both 
showed no cardiovascular outcome differences between the three groups at similar level of 
blood pressure control (10). The conclusion of Stop-Hypertension 2 study and NORDIL 
study show that CCBs are equally effective in cardiovascular outcome trials of low- medium 
risk patients. 
MRC Trial (Medical Research Council Trial) (11) found no difference in cardiovascular 
outcomes between thiazide diuretic and Propanolol, but there was a significant increased 
risk of stroke in the Propanolol arm. This trial was predominantly in middle aged men with 
mean diastolic pressure 99-109 mm Hg. A subsequent MRC trial (12) comparing Atenolol to 
Hydrochlorothiazide plus Amiloride suggested Beta-blockers did not reduce cardiovascular 
mortality or coronary events but did reduce the incidence of cerebrovascular incidents, 
while diuretics reduced all of these endpoints. 
In the ACCOMPLISH trial (Avoiding Cardiovascular Events Through Combination 
Therapy in Patients Living With Systolic Hypertension), 11,500 patients with hypertension 
and mean baseline BP 145/80, who are at high risk of cardiovascular events, were randomly 
assigned to a combination therapy with Benazepril plus either Amlodipine or 
hydrochlorthiazide (12.5 to 25 mg/day) (13). At 36 months, the trial was terminated early. 
Benazepril- Amlodipine therapy was associated with significant reductions in the primary 
composite end point of fatal or non fatal cardiovascular events (9.6 versus 11.8 percent) and 
the secondary end point of cardiovascular death or non fatal MI or stroke (5.0 versus 6.3 
percent). The mean blood pressure was slightly (about 1mm Hg) lower in the Benazepril-
Amlodipine arm (132/73 versus 133/74), a difference that was too small to account for the 
large difference in outcomes. In a subset of 573 patients with 24 hour Ambulatory BP 
monitoring there was a non-significantly higher BP (1.3/0.3 mm Hg) in the Benazepril- 
Amlodipine group. The benefits seen in the Benazepril-Amlodipine arm appear to be 
independent of blood pressure lowering. The study also cannot distinguish benefit from 
Benazepril-Amlodipine and harm from Benazepril-hydrochlorthiazide arms. 
2.1 Choice of antihypertensive medications in essential hypertension 
The 2007 American heart Association and 2007 European Society of Hypertension (14) and 
European Heart Association (15) concluded that it is the amount of Blood Pressure 
reduction and not the class of drug used which determines the reduction in Cardiovascular 
risk in patients with Hypertension. 
The initial choice recommended by the Joint National Commission 7(JNC7) for 
uncomplicated essential hypertension is thiazide diuretics (16) If thiazides fail to control 
blood pressure then ACEI/ARBs, CCBs or BB can be added. The use of these drugs is 
guided by cost or comorbid conditions for specific therapies. Post-ACCOMPLISH trial, since 
most patients with mild hypertension end up using more than one drug, either long acting 
ACE inhibitor/ARB or dihydropyridine calcium channel blocker could be recommended as 
first line therapy. Those with moderate to severe hypertension (Stage II) as defined by JNC7 
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having blood pressures greater than 20/10 mm Hg above goal should be considered initially 
for dual therapy. The combination of long acting ACEI/ARB with a dihydropyridine CCB 
would probably be the therapy of choice given the favourable results in the ACCOMPLISH 
trial. 
 
Trial Population 
Studied 
Intervention Outcome Comments 
TOHP Trial 
(Hypertension 
Prevention) 
placebo 
controlled trial 
of 2812 
hypertensive 
patients 
Lifestyle 
modification on BP 
control. 
Weight loss most effective 
Calcium, Magnesium, fish 
oil – no effect. 
 Small BP differences (-4/-3 
mm Hg) associated with 
significant reduction in 
stroke (23%), coronary 
disease (15%) & mortality 
(14%). 
 
 
TOMHS Trial 
(Treatment of 
Mild 
Hypertension)  
predominant 
white 
population 
Efficacy of 5 major 
first line drugs on 
BP control 
Efficacy similar  
But Amlodipine had 
highest percentage of 
responders to 
monotherapy 
 
 
ALLHAT Trial 
(Antihypertensive 
and Lipid 
Lowering to 
prevent Heart 
Attack) 
 45,000 patients 
with 
hypertension 
and one 
additional 
coronary disease 
risk factor   
Randomly assigned 
chlorthalidone 
(12.5-25 mg/day) 
to one of three 
other arms: CCB 
(Amlodipine), 
ACEI (Lisinopril) 
and alpha 
adregenic blocker 
(Doxazosin) 
Primary outcome (fatal 
coronary disease, non fatal 
myocardial infarction) 
similar for all three agents.
**Doxazosin arm 
prematurely terminated 
due to increased risk of 
heart failure vs diuretics  
a) CCB vs diuretic - 
higher rate of heart failure 
but other secondary CV 
outcomes similar 
 b) ACEI vs diuretic- 
higher combined 
cardiovascular outcomes, 
stroke and heart failure 
a) & b) attributed to better BP 
control in diuretic arm 
 For hypertensives 
at high risk for 
cardiovascular 
disease, diuretics, 
CCB and ACEI 
offer similar in 
protection vs fatal 
coronary disease & 
nonfatal 
myocardial 
infarction 
ANBP2 Trial 
(Second 
Australian 
National Blood 
Pressure) 
Prospective trial 
of 6000 elderly 
hypertensive 
patients 
ACEI (Lisinopril) 
vs diuretic 
(Hydrochlorothiazi
de)  
Primary outcome: all 
cardiovascular events 
(myocardial infarction, 
sudden death from cardiac 
events)- 
ACEI arm had better 
outcomes vs diuretic  
 
Fatal events same in both 
arms, but non-fatal 
cardiovascular events were 
less in ACEI arm 
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Stop-
Hypertension 2 
Trial  
Low-medium 
CV risk 
hypertensive 
patients  
ACEI (Lisinopril) 
vs. 
dihydropyridine 
CCB Felodipine or 
Isradipine vs Beta-
blocker and /or 
diuretic  
No difference in 
cardiovascular end points 
CCBs equally 
effective in 
cardiovascular 
outcome 
NORDIL Trial 
(Nordic Diltiazem 
Trial)  
Low-medium 
CV risk 
hypertensive 
patients. 
Comparing CCB 
(Diltiazem) 
combined with 
either diuretic or 
Beta-blockers or 
both. 
No cardiovascular 
outcome differences 
CCBs equally 
effective in 
cardiovascular 
outcome 
 
MRC Trial 
(Medical Research 
Council Trial) 
Middle aged 
men with mean 
diastolic BP 99-
109. 
Thiazide diuretic vs 
Propanolol. 
 
 
Second MRC trial 
comparing 
Atenolol to 
Hydrochlorothiazi
de plus Amiloride 
No difference in 
cardiovascular outcomes 
but significant increased 
stroke risk in Propanolol 
arm 
 
 Beta-blockers did not 
reduce cardiovascular 
mortality or coronary 
events but reduced 
cerebrovascular  
incidents, while diuretics 
reduced all these 
endpoints
 
ACCOMPLISH 
trial (Avoiding 
Cardiovascular 
Events Through 
Combination 
Therapy in 
Patients Living 
With Systolic 
Hypertension 
11,500 patients 
with 
hypertension 
and baseline BP 
145/80, high risk 
of 
cardiovascular 
events 
Benazepril plus 
either Amlodipine 
or 
hydrochlorthiazide 
(12.5 to 25 
mg/day).  
 
  
Terminated early
 
Benazepril- Amlodipine 
showed significant 
reductions in primary 
composite end point (fatal 
or non fatal cardiovascular 
events) and secondary end 
point (cardiovascular 
death or non fatal MI or 
stroke)
Cannot distinguish 
benefit from 
Benazepril-
Amlodipine vs. 
harm from 
Benazepril- 
hydrochlorthiazide  
Table 1. Summary of Trials in Patients with Essential Hypertension 
3. Renal trials  
Renal outcome trials can be divided into those pertaining to patients with diabetic versus 
non- diabetic kidney disease. In the latter, the focus has been on short-term reduction of 
proteinuria and long term delay in progression of kidney disease. On the other hand, in 
diabetic kidney disease trials have focused on reduction of protein excretion as a surrogate 
end point since it correlates directly with the rate of decline in renal function. 
a. Non- Diabetic kidney disease: 
Most trials on reduction of proteinuria have focused on ACEI. This class of drugs has been 
known to reduce intraglomerular pressure mainly by inhibition of Angiotensin II- mediated 
efferent arteriole vasoconstriction. In addition, ACEI alter the permaselective properties of 
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the glomerular basement membrane and have antifibrotic effects that are thought to further 
reduce proteinuria. 
How do other drugs compare with ACEI in proteinuria reduction? 
In a trial (17) comparing non-dihydropyridine CCBs (Verapamil and Diltiazem) versus 
dihydropyridine CCBs (Amlodipine and Nifedipine), the former were found to have a 
significant (30%) reduction in proteinuria while the latter had no decrease or even an 
increase in protein excretion. It is postulated that DHP CCBs cause afferent arteriole 
dilatation allowing more of the aortic pressure to be transmitted to the glomerulus. Hence 
despite lowering of systemic blood pressure the intraglomerular pressure (IGP) remains 
elevated without significant decrease in proteinuria. Similarly Beta-blockers, diuretics, 
alpha-blockers have no effect on reducing IGP and hence proteinuria (18,19,20). Studies 
have also examined the comparative effectiveness of Angiotensin II receptor blockers (21). 
In one study of patients with IgA nephropathy Enalapril and Irbesartan had similar 
effects on proteinuria (22). The antiprotenuric effect of ACEI and A2RBs increases when 
used at supramaximal doses. For instance, Temlisartan 80 mg when used twice vs. once 
daily had significantly greater decline in proteinuria and progression of kidney disease, 
despite similar BP reduction. Additionally, combination therapy with ACEI and A2RBs 
has shown significant beneficial effect on proteinuria and kidney disease progression, 
more so when used in maximal or submaximal doses than maximum dose of either drug 
alone (23). This meta-analysis comparing combination therapy at submaximal doses to 
either agent alone at maximal doses confirmed these findings with greater reduction in 
proteinuria. 
While the above trials focused on reduction of proteinuria, other trials in non-diabetics have 
shown benefits of ACEI in reducing progression to chronic kidney disease. 
Though, the ALLHAT Trial (24) of more than 44,000 hypertensive patients failed to show 
superiority of ACEI, DHP-CCBs and alpha-blockers over a thiazide diuretic with respect to 
cardiovascular outcomes. In post hoc analysis neither ACEI nor CCB was superior to 
thiazide diuretic with respect to renal outcomes. This trial was contradictory to other 
primary renal outcome trials that showed benefit of ACEI over other drug classes. Some of 
the factors responsible for this controversy will be explored.The ALLHAT did not select 
patients with renal disease as an inclusion criterion, since it was not mainly a renal outcome 
trial. Blood pressure was also lower in thiazide arm as compared to the other arms hence 
equivalency of blood pressure was not achieved. Furthermore, no urine tests were 
performed even though renal outcomes were studied thus failing to identify those who were 
at highest risk for progression and most likely to derive benefit from ACEI i.e. patients with 
proteinuric diabetic kidney disease. Hence, in the ALLHAT trial little or no attention was 
paid to kidney function, consequently the results of ALLHAT regarding renal outcomes 
remain unresolved. 
REIN Trial (Ramipril Efficacy in Nephropathy) of non-diabetic chronic kidney disease 
patients treated with Ramipril or placebo plus other medications to a target diastolic 
pressure less than 90 mm Hg. At same level of blood pressure control, the Ramipril group 
had a significant decrease in rate of decline of GFR (25). The disparity was predominantly so 
significant in groups excreting > 3 grams/day, necessitating premature termination of the 
study in favour of the Ramipril group. As a follow-up to this study patients excreting > 
3grams/day on Ramipril were continued on same drug, but those on placebo were also 
switched to Ramipril. Analysis of this follow-up revealed that patients assigned as well as 
those shifted to Ramipril, had significant attenuation in the rate of deterioration of renal 
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function compared to the conventional therapy group. Longer follow-up at 5 years showed 
that some patients in the Ramipril group actually had an increase in GFR. Further analysis 
also revealed that Ramipril was efficious in patients with less severe proteinuria (>1 gram 
but < 3 grams/day) and also decreased the rate of decline in GFR in all tertiles of GFR (low: 
11-33 ml/min/1.73m2, middle: 33-51 ml/min/1.73 m2, high: 51-101 ml/min/1.73m2).In the 
REIN 2 Trial (26), DHP CCB’s were once again found to be non efficacious in patients with 
chronic kidney disease. In this trial patients on Ramipril (up to 5 mg) were randomly 
assigned to conventional (DBP<90) or intensive BP control (DBP<80) groups. Felodipine was 
added for intensive blood pressure control. After 19 months there was no significant 
difference in proteinuria, decline in GFR or progression to ESRD in the intensive Felodipine 
treated group despite lower blood pressure. 
MDRD Trial (Modification of Diet in Renal Disease) compared two groups: one with 
usual blood pressure control (target 140/90) and one with aggressive control (target 125/75) 
over a three-year period. The achieved blood pressures were 130/80 and 125/75 
respectively. The patients were further subdivided into 3 groups by severity of proteinuria, 
i.e.: < 1 gram, 1-3 grams and > 3 grams of protein excretion per day. More than half the 
patients were treated with ACEI and the mean GFR of the approximately 600 patients was 
39 ml/min (27). The patients with <1 gram/day proteinuria had the slowest decline in  
GFR of the three groups (approximately 3 ml/year). No difference was seen in the low 
blood pressure group. Patients in 1-3 gram/day group had a more rapid deterioration  
in GFR with mild benefit in lower BP group. Those in >3 gram/day group had the fastest 
rate of loss in GFR but at the same time there was a substantial attenuation in rate of  
GFR decline in the low blood pressure group. This study showed that the greater the 
proteinuria, the faster is the decline in GFR. However with blood pressure control the rate of 
decline in GFR can be attenuated. While this trial did not evaluate the efficacy of ACEI, the 
Benazepril Trial did. 600 patients with chronic kidney disease (diabetic and non diabetic but 
not hypertensive nephrosclerosis) on treatment for blood pressure control were randomised 
to either Benazepril or placebo (28). The Benazepril group had significantly lower 
proteinuria, greater reduction in blood pressure, less doubling of serum creatinine and 
progression to dialysis. Though the drug was compared to placebo, it did show the efficacy 
of ACEI. 
The role of combination ACEI with A2RB’s was addressed in the COOPERATE Trial 
(Combination Treatment of Angiotensin II receptor blocker and Angiotensin converting 
enzyme inhibitor in non diabetic renal disease) where Losartan 100mg/day, Trandolapril 
3mg/day or a combination of the two were compared (29). All the three arms of the trial 
had the same blood pressure reduction. However the largest decrease in proteinuria was 
seen in the combination group (77 percent) versus Losartan (42 percent) or Trandolapril (44 
percent). The composite end point of doubling serum creatinine or progression to ESRD was 
less with combination (11 percent) therapy than either Losartan (23 percent) or Trandolapril 
(23 percent). In the COOPERATE trial, those who could not tolerate maximum doses of 
combination therapy were treated with sub-maximal doses. Even then the antiprotenuric 
effects were greater than with either of the single agents. This was further verified in 
another trial (30) comparing Losartan 50 mg/day, Benzalapril 10 mg/day, Losartan 
(25mg/day) plus Benzalapril 5 mg/day. Although similar blood pressure lowering was 
observed, combination therapy at half the dose resulted in significantly lower proteinuria 
than either drug alone. 
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Non-Diabetic 
Trial 
Population 
Studied 
Intervention Outcome Comments 
REIN Trial 
(Ramipril 
Efficacy in 
Nephropathy) 
Non-diabetic 
chronic kidney 
disease patients 
Ramipril or 
placebo 
 Ramipril group had 
significant decrease in rate 
of GFR decline especially 
significant in groups 
excreting > 3 g/d but also in 
less severe proteinuria 
DHP CCB’s non efficacious 
ACEi significant 
attenuation in rate 
of deterioration of 
renal function 
MDRD Trial 
(Modification of 
Diet in Renal 
Disease) 
 Usual (140/90) vs 
aggressive BP 
control (125/75) 
The greater the proteinuria, 
the faster is the decline in 
GFR 
With BP control rate of GFR 
decline attenuated 
 
 
Benazepril Trial  600 patients 
with chronic 
kidney disease 
(diabetic and 
non diabetic but 
not hypertensive 
nephrosclerosis)
Benazepril or 
placebo 
 
 
Benazepril significantly 
lower proteinuria, greater 
reduction in BP, less 
doubling of serum 
creatinine and progression 
to dialysis 
Trial demonstrates 
efficacy of ACEI 
COOPERATE 
Trial 
(Combination 
Treatment of 
Angiotensin II 
receptor blocker 
& Angiotensin 
converting 
enzyme 
inhibitor in non 
diabetic renal 
disease) 
Non-diabetic 
renal disease 
Losartan  
Trandolapril or a 
combination 
Doubling serum creatinine 
or progression to ESRD was 
less with combination than 
either Losartan or 
Trandolapril 
 
Even with sub-maximal 
doses of combination 
therapy, antiprotenuric 
effects greater than with 
either of the single agents  
Largest decrease in 
proteinuria seen in 
combination group 
Table 2. A. Summary of Trials in patients with renal disease and renal outcomes (Renal 
Trials). NON-DIABETIC 
b. Trials in Diabetic kidney disease: 
These are divided into three major groups. 
i.  Prevention of Incipient Diabetic Nephropathy- BENEDICT Trial 
ii. Trials on microalbuminuric Diabetic Nephropathy- HOPE, IRMA, MARVAAL Trials 
iii. Trials on overt Diabetic nephropathy-IDNT, RENAAL, DETAIL, AVOID, ONTARGET 
Trials 
i. Prevention of Incipient Diabetic Nephropathy 
BENEDICT Trial (Bergamo Diabetic Nephrogenic Trial) is a prospective (31), randomised 
trial in 1209 hypertensive patients with type 2 diabetes mellitus and normal urine albumin 
excretion whose aim was to prevent the progression to microalbuminuria. Patients were 
randomised to a 3-year trial of non DHP CCB (Verapamil 240 mg/day), ACEI (Trandolapril 
2 mg/day), combination (Verapamil 180 mg/day and Trandolapril 2mg/day) and placebo. 
The primary outcome was the development of persistent microalbuminuria, which occurred 
at a rate of 11.9% in Verapamil only group, 6 %in Trandolapril group, 5.7 % in the 
combination group and 10% in the placebo. The study showed that Verapamil was similar 
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to placebo and the use of ACEI was effective in reducing the incidence of microalbuminuria 
whereas the addition of non DHP CCB did not decrease the risk of its development. It can 
be concluded that ACEIs are the medication of choice in reducing microalbuminuria in 
diabetic nonmoalbuminuric hypertensive patients. 
ii. Trials on microalbuminuric Diabetic Nephropathy 
PRIME Trial (Program for Irbesartan Mortality and Morbidity Evaluation) consisted of 
two large trials comparing IDNT (Irbesartan in Diabetic Nephropathy Trial) (32,33,34) and 
IRMA (Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria), which evaluated 
the renal and cardiovascular effects of Irbesartan on hypertensive patients with diabetes 
(40). In particular, these two large trials addressed the question of whether ARB can prevent 
the development of clinical proteinuria (IRMA) or delay the progression of nephropathy 
(IDNT) in type2 diabetes. The latter will be discussed with the trials on overt nephropathy. 
IRMA Trial (Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study 
Group), a multicentre, randomized, double-blind, placebo-controlled trial, evaluated the 
effect of Irbesartan in preventing the onset of clinical proteinuria in patients with type 2 
diabetes, hypertension and microalbuminuria (35). A total of 590 patients were randomized 
to receive therapy with Irbesartan 150 mg, Irbesartan300 mg, or placebo. Additional 
antihypertensive agents (excluding ACE-I, ARB, and Dihydropyridine calcium-channel 
blockers) were allowed in each arm of the study to achieve the target BP of<135/85 mmHg. 
The primary end point of the study was the onset of overt nephropathy, defined as the 
occurrence of a urinary albumin excretion rate >200 µg/min and at least 30%higher than 
baseline. Secondary outcomes were the regression to normoalbuminuria and changes in 
albuminuria and renal function. 
The mean duration of follow-up was 2 yr. The average BP during the course of the study 
was 143/83 mmHg in the 150-mg group, 141/83 mmHg in the 300-mg group, and 144/83 
mmHg in the placebo group. Although the difference in systolic pressure between the 
Irbesartan 300-mg group and the placebo group was only 3mmHg, it was statistically 
significant. With respect to the primary end point, Irbesartan 150and 300 mg showed a 
reduction of 44 and 68%, respectively versus placebo. Moreover, albuminuria was reduced 
by 38% in the 300-mg group, 24% in the150-mg group, and remained unchanged in the 
usual care group. In this last group, the reduction in BP from 153/90 to 144/83mmHg 
resulted in stabilization of albuminuria. In addition, regression to normoalbuminuria was 
more frequent in the patients who were treated with the higher dose of Irbesartan (17, 12, 
and 10.5/100 patient-years in the 300-mg, 150-mg, and placebo group, respectively). On the 
basis of these data, Irbesartan seems to be much more effective in preventing the 
development of clinical proteinuria and in favouring the regression to normoalbuminuria 
than conventional therapy. The renoprotective, dose-dependent effect of Irbesartan seems to 
be independent of its BP-lowering effect, even though the 3-mmHg difference in systolic 
pressure may have played a role. Similar findings were shown in other trials as discussed 
below. 
HOPE Trial (Heart Outcomes and Prevention Evaluation) and MICRO-HOPE 
(Microalbuminuria and Renal Outcomes) Trial retrospectively analysed changes of 
proteinuria over4.5 yrs., and compared Ramipril’s effects to placebo in9297 participants, 
including 3577 with diabetes and 1956 with microalbuminuria.  In particular, one of every 
three participants with diabetes developed new microalbuminuria, and one of five diabetic 
participants with microalbuminuria developed overt nephropathy (36,37). We know little 
about the development of new microalbuminuria in type 2 diabetes; these data indicate that 
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it develops ata surprisingly high rate. Assuming a constant rate of appearance of new overt 
nephropathy over time, the HOPE study also confirms that approximately 50% of 
microalbuminuric people with type2 diabetes will develop overt nephropathy in 10 years 
(38). ACE inhibition was shown to be effective in reducing the progression of albuminuria in 
all participants including the subgroups with and without diabetes mellitus. 
MARVAL Trial (Microalbuminuria Reduction with Valsartan) compared Valsartan 
80mg/day versus Amlodipine 5 mg/day in type 2 diabetic microalbuminuric patients (39). 
A target BP of 135/85 mm Hg was aimed for by double dosing after four weeks followed by 
addition of bendrofluazide and Doxazosinas needed. The primary end point of percentage 
reduction in proteinuria was 44 percent with Valsartan and 8 percent with Amlodipine. For 
the same level of attained BP, Valsartan lowered albuminuria more effectively than 
Amlodipine in patients with type 2 diabetes and microalbuminuria, including the subgroup 
with baseline normotension. This indicates BP-independent antiprotenuric effect of 
Valsartan. Moreover, more patients reverted to normoalbuminuria with Valsartan. 
Recommendations clinical pearl The above three studies clearly show that blocking of the 
Renin Angiotensin Aldosterone System (RAAS) with ACEI or ARBs in patient with type II 
diabetes mellitus reduces the risk of progression of microalbuminuria to overt proteinuria 
and may even revert it back to normoalbuminuria, both in hypertensive and normotensive 
patients. 
iii. Trials on overt Diabetic nephropathy  
For patients who already have overt nephropathy, trials in type 1 and type 2 diabetics show 
benefits of ACEI and ARBs in reducing progression to end stage renal disease (ESRD) as will 
be discussed. In Type 1 DM the largest trials (40,41) were in patients who already had overt 
nephropathy with serum creatinine less than 2.5 mg/dl who were randomised to either 
Captopril or placebo. After four years there was significant decrease in rate of decline in 
renal function in the Captopril arm versus placebo. This rate was reduced from 1.4 mg/dl in 
the placebo group to 0.6 mg/dl in the Captopril group. The beneficial effect was seen mainly 
in patients whose initial serum creatinine was greater than 1.5 mg/dl, while no benefit was 
seen with lower baseline serum creatinine likely because the rate of progression was very 
slow in this group (0.1-0.2 mg/dl/year). The beneficial effect of Captopril was seen in both 
normotensive and hypertensive patients. However, it has been suggested that reducing BP 
to less than 120/75 regardless of the agent may slow progression of kidney disease (42). 
In another study (43) of 301 patients with overt nephropathy of whom 271 were 
hypertensive and 30 were normotensive, the remission rates (defined as proteinuria less 300 
mg/day) and regression rates (defined as rate of decline in GFR< 1 ml/min/year) were 
significantly greater in the lower blood pressure groups. The main antihypertensive drugs 
were ACEI in about 179 patients. The lower blood pressure group (mean arterial pressure 93 
mm Hg) had remission and regression rates of 58 and 42 percent while the higher blood 
pressure group (mean arterial pressure 113 mm Hg) had rates of only 17 and 7 percent, after 
a mean follow up of 7 years. Thus aggressive blood pressure control in patients with overt 
nephropathy will induce greater remission and regression rates, especially when ACEI are 
used. 
In Type 2 diabetics with overt nephropathy much of the prevailing evidence is with ARBs. 
Similar to the trials described above, control of blood pressure is essential to limit 
progression to ESRD however the optimal lower limit is not defined. The UKPDS Trial 
(United Kingdom Prospective Diabetes Study) showed that every 10 mm Hg decrease in 
systolic blood pressure reduced diabetic complications by 12 percent, with the lowest risk 
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below 120 mm Hg (43). However in the IDNT Trial (Irbesartan Diabetic Nephropathy Trial) 
lowering SBP less than 120 mm Hg was associated with increased risk of all cause 
cardiovascular mortality (33,34). However in the group with increased cardiovascular 
mortality there was a higher incidence of underlying heart disease and heart failure. 
Moreover, the number of patients was too low to determine if the effect of low blood 
pressure was independent of prior cardiac disease. The two major trials which have clearly 
shown the benefits of ARBs in patients with proven nephropathy due to Type 2 DM will be 
reviewed. 
The IDNT Trial (Irbesartan Diabetic Nephropathy Trial) of 1715 patients with diabetic 
nephropathy who were randomly assigned to Irbesartan 300 mg/day versus Amlodipine 10 
mg/day versus placebo (33,34). After 30 months of follow up, the composite end points of 
development of ESRD or death from any cause were 23% and 20 % lower with Irbesartan 
than Amlodipine and placebo respectively. The rates for doubling serum creatinine were 
also 37% and 30 % lower for Irbesartan than Amlodipine and placebo respectively (33,34,35). 
The RENAAL Trial (Reductions of endpoints in NIDDM with the Angiotensin II Antagonist 
Losartan) of 1513 patients with type 2 diabetic nephropathy, in which patients were 
assigned Losartan (50-100 mg/day) versus placebo with additional drugs added for further 
blood pressure control (except ACEI). The composite end points of doubling serum 
creatinine or ESRD were 25% and 28 % lower with Losartan than placebo (44). Both the 
above studies underline the positive effect of ARBs on progression of diabetic nephropathy. 
The DETAIL Trial is the only study which offered head to head comparisons between ACEI 
and ARBs for diabetic nephropathy in type 2 diabetics (45). Temlisartan versus Enalapril 
were compared in patients with albuminuria (defined as micro and macroalbuminuria).  
After five years of follow-up there was a smaller but non-significant decline in GFR with 
Enalapril versus Temlisartan (14.9 ml/min versus 17.9 ml/min per 1.73 m2). Both arms had 
similar secondary end points of urine albumin excretion, doubling serum creatinine, 
progression to ESRD and cardiovascular events. 
Combination ACEI and ARBs in diabetic proteinuric kidney disease have not been studied 
in large trials. Nevertheless, three small studies (46,47,48) have shown benefit of 
combination therapy over either ACEI or ARBs (the latter two used at either maximal or 
sub-maximal dose). 
While diuretics are not known to have antiprotenuric effects despite lowering blood 
pressure, Aldosterone antagonists either used alone or in combination with ACEI or ARBs 
have been shown to reduce proteinuria. In a trial of 59 patients with Type 2 diabetes and 
nephropathy on ACE or A2RBs, the addition of Spironolactone 50 mg/day versus placebo 
was associated with a 40% reduction in proteinuria and 7/3 mm Hg decrease in BP (49). 
Eplernone 50 mg/day when added to ACEI in patients with type 2 diabetes was associated 
with a significant 40% reduction in proteinuria compared to placebo (50). While no long 
term studies have shown a benefit of Aldosterone blockers in reducing the rate of loss of 
GFR, their antiprotenuric and BP lowering effects would be expected to translate into 
nephroprotection.  
GEMINI Trial (Metabolic Effects of Carvedilol vs. Metoprolol in Patients with Type 2 
Diabetes Mellitus and Hypertension)1200 participants with type 2 diabetes mellitus 
showed that when Carvedilol was added to blockers of RAAS improvements not only in 
glycaemic control but also in risk of developing microalbuminuria were seen. These were 
markedly reduced over Metoprololat similar levels of blood pressure control. (51). It was 
also noted that those without microalbuminuria had a 7/4 mm Hg greater reduction in 
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blood pressure as compared to those with microalbuminuria (52). This observation supports 
previous data of a blunted vascular response associated with microalbuminuria. It also 
suggests that not all have the same detrimental effect on diabetes and the risk of its 
development.  
The AVOID Trial (Aliskerin in the Evaluation of Proteinuria in Diabetes) of 599 patients 
with Type 2 diabetes and nephropathy, evaluated the renoprotective effects of dual 
blockade of the renin angiotensin aldosterone system (RAAS) by adding treatment with 
Aliskerin (maximum dose 300 mg daily), an oral direct renin inhibitor, to treatment with the 
maximal recommended dose of Losartan (100 mg daily) (53). At 6 months the primary end 
point of reduction in albumin- creatinine ratio was a mean of 20% in Aliskerin group versus 
placebo with over 50% reduction in 25% of patients in Aliskerin group versus 12.5% in 
placebo. This was despite a small difference in BP between the two groups (systolic 2mm 
Hg/ diastolic 1 mm Hg) favouring Aliskerin. Clinical pearl This suggests Aliskerin may 
have renoprotective effects that are independent of blood pressure lowering effects in 
hypertensive patients with type 2 diabetes and nephropathy who are already receiving the 
recommended therapy. 
The ONTARGET trial (The Ongoing Telmisartan alone and in combination with 
Ramipril Global Endpoint Trial), in which 25,620 patients with vascular disease or diabetes 
were randomized to the ACE inhibitor Ramipril, ARB Telmisartanor the combination of the 
two drugs (54). The primary renal outcome was a composite of dialysis, doubling of serum 
creatinine and death. The number of events of primary composite outcomes was similar for 
Ramipril and Temlisartan but was increased with combination therapy. Although the 
combination therapy reduced proteinuria more than either single therapy, overall it 
worsened major renal outcomes. 
Finally, the controversial meta-analysis by Casas (55) will be discussed. This included 
thirteen trials with 37,089 subjects. Casas concluded that drugs which inhibit the Renin 
Angiotensin Aldosterone system (RAAS) provide only marginal benefit for nondiabetic 
kidney disease and no benefit in diabetic renal disease. The authors state that if there is a 
benefit of ACEI or ARBs in diabetics, it is simply due to better blood pressure control, which 
was 2 to 7 mm Hg lower in the ACEI groups. When their analysis was limited to studies 
with no evident blood pressure difference, no benefit was identified. Similar findings were 
noted in the ABCD trial (Appropriate Blood Pressure Control Trial) in patients with 
microalbuminuria and mean baseline GFR of 84 ml/min. No difference in renal outcomes at 
5 years was observed between ACEI and calcium channel blockers when their BP was 
lowered to below 130/80 mm Hg (56).  
 
Trial 
Diabetic 
Population 
Studied 
Intervention Outcome Comments 
BENEDICT 
Trial (Bergamo 
Diabetic 
Nephrogenic 
Trial) 
1209 
hypertensive 
patients with 
type 2 diabetes 
mellitus and 
normal urine 
albumin 
excretion  
  
Non DHP CCB 
Verapamil vs ACEI 
Trandolapril vs 
combination vs 
placebo 
Primary outcome:  
Development of persistent 
microalbuminuria. 
 
Verapamil similar to placebo 
 
 ACEI effective in  
reducing  
incidence of  
microalbuminuria 
ACEIs are of choice 
in reducing 
microalbuminuria in 
diabetic nonmo-
albuminuric 
hypertensive patients 
PRIME Consisted of Whether ARB can   
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Trial(Program 
for Irbesartan 
Mortality and 
Morbidity 
Evaluation) 
two large trials 
on type 2 
diabetics: 
 
 IDNT 
(Irbesartan in 
Diabetic 
Nephropathy 
Trial) 
 
IRMA 
(Irbesartan in 
Patients with 
Type 2 
Diabetes & 
Microalbumin
uria) 
prevent 
development of 
clinical proteinuria 
(IRMA) or delay 
progression of 
nephropathy 
(IDNT)  
IRMA Trial 
(Irbesartan in 
Patients with 
Type 2 
Diabetes and 
Microalbumin
uria Study 
Group) 
Patients with 
Type 2 
Diabetes and 
Microalbumin
uria. 
Irbesartan 150 mg 
or Irbesartan 300 
mg vs placebo 
 
  
 
Primary end point: Onset of 
overt nephropathy- 
Irbesartan 150and 300 mg 
showed a reduction vs placebo
 
Secondary outcomes: 
Regression to 
normoalbuminuria and 
changes in albuminuria & 
renal function- 
Regression more frequent with 
higher Irbesartan dose  
Irbesartan more 
effective in 
preventing 
development of 
clinical proteinuria 
and regression to 
normoalbuminuria 
than conventional 
therapy 
 
HOPE Trial 
(Heart 
Outcomes and 
Prevention 
Evaluation) 
and MICRO-
HOPE (Micro-
albuminuria 
and Renal 
Outcomes) 
Trial  
9297 
participants, 
including 3577 
with diabetes 
and 1956 with 
Microalbumin
uria 
Follow changes of 
proteinuria and 
compare 
Ramipril’s vs 
placebo  
Approximately 50% of 
microalbuminuric people with 
type2 diabetes will develop 
overt nephropathy in 10 years 
 
ACE inhibition effective in 
reducing progression of 
albuminuria in all, including 
subgroups with and without 
diabetes mellitus 
 
 
 
MARVAL 
Trial 
(Microalbumi
nuria 
Reduction 
with 
Valsartan) 
Patients with 
type 2 diabetes 
and 
microalbumin
uria 
Valsartan vs 
Amlodipine 
Primary end point: reduction 
in proteinuria-  
 
Valsartan more effective 
including subgroup with 
baseline normotension & more 
patients reverted to normo-
albuminuria 
 
 
BP-independent 
antiprotenuric effect 
of Valsartan 
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Trials on 
Overt Diabetic 
Nephropathy    
Type 1 DM 
with overt 
nephropathy & 
serum 
creatinine < 2.5 
mg/dl 
 
 
 
 
301 Patients 
with overt 
nephropathy, 
271 
hypertensive & 
30 
normotensive 
 
Randomised to 
either Captopril or 
placebo 
 
 
 
 
 
Normal vs lower 
BP groups 
 
Main 
antihypertensive 
drugs   
were ACEI in 179 
patients 
Significant decrease in rate of 
decline in renal function in the 
Captopril arm 
 
Beneficial effect of Captopril in 
both normotensive & 
hypertensive patients 
 
 
Significantly greater 
nephropathy remission & 
regression rates in lower BP 
group 
 
Aggressive BP 
control in patients 
with overt 
nephropathy will 
induce greater 
remission & 
regression rates, 
especially when 
ACEI are used 
The UKPDS 
Trial (United 
Kingdom 
Prospective 
Diabetes 
Study) 
 Showed that every 
10 mm Hg 
decrease in systolic 
BP reduced 
diabetic 
complications by 
12 %, with lowest 
risk below 120 mm 
Hg 
  
IDNT 
Trial(Irbesarta
n Diabetic 
Nephropathy 
Trial 
1715 patients 
with diabetic 
nephropathy 
Irbesartan vs 
Amlodipine vs 
placebo 
 
 
Composite end points: 
development of ESRD or death 
from any cause- lower with 
Irbesartan than Amlodipine 
and placebo 
 
Doubling serum creatinine 
lower for Irbesartan. 
 
  
Positive effect of 
ARBs on progression 
of diabetic 
nephropathy 
 
Of note: lowering 
SBP < 120 mm Hg 
associated with 
increased risk of all 
cause cardiovascular 
mortality. However 
this group had higher 
incidence of 
underlying heart 
disease & heart 
failure and number of 
patients was too low 
to determine if lower 
BP effect was 
independent of prior 
cardiac disease 
RENAAL Trial 
(Reductions of 
endpoints in 
NIDDM with 
Type 2 diabetic 
nephropathy 
Effect of Losartan 
(50-100 mg/day) 
vs placebo  
 
Composite end points of 
doubling serum creatinine or 
ESRD: lower with Losartan  
Positive effect of 
ARBs on progression 
of diabetic 
nephropathy 
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the 
Angiotensin II 
Antagonist 
Losartan)  
DETAIL Trial Type 2 
diabetics with 
diabetic 
nephropathy  
(micro and 
macro 
albuminuria) 
Temlisartan vs 
Enalapril on 
diabetic 
nephropathy 
progression  
A smaller but non-significant 
decline in GFR with Enalapril 
vs Temlisartan 
 
Similar secondary end points 
of urine albumin excretion, 
doubling serum creatinine, 
progression to ESRD & 
cardiovascular events 
 
 
GEMINI 
Trial(Metaboli
c Effects of 
Carvedilol vs. 
Metoprolol in 
Patients with 
Type 2 
Diabetes 
Mellitus and 
Hypertension) 
1200 
participants 
with type 2 
diabetes 
mellitus 
Carvedilol vs 
Metoprolol was 
added to RAAS 
blockers 
 
Improvements in glycaemic 
control & risk of developing 
microalbuminuria with 
carvedilol vs Metoprolol 
 
 
Confirms blunted 
vascular response 
associated with 
microalbuminuria 
  
Suggests that not all 
beta Blockers have 
same detrimental 
effect on diabetes & 
risk of its 
development 
AVOID Trial 
(Aliskerin in 
the Evaluation 
of Proteinuria 
in Diabetes) 
599 patients 
with Type 2 
diabetes and 
nephropathy 
dual blockade: 
adding Aliskerin to 
maximal dose of 
Losartan vs 
placebo  
Primary end point: reduction 
albumin- creatinine ratio- 
 
 20% in Aliskerin group vs 
12.5% in placebo despite a 
small difference in BP  
Aliskerin may have 
renoprotective effects 
independent of BP 
lowering 
ONTARGET 
trial (The 
Ongoing 
Telmisartan 
alone and in 
combination 
with Ramipril 
Global 
Endpoint 
Trial), 
 25,620 patients 
with vascular 
disease or 
diabetes 
ACE inhibitor 
Ramipril vs ARB 
Telmisartan vs 
combination  
 
 
Primary renal outcome: 
composite of dialysis, doubling 
of serum creatinine & death: 
similar for Ramipril and 
Temlisartan but was increased 
with combination therapy 
 
Although combination therapy 
reduced proteinuria more than 
either single therapy, overall it 
worsened major renal 
outcomes 
 
 
Meta-analysis 
by Casas  
 
 
 
Thirteen trials 
37,089 subjects
 
Drugs which inhibit RAAS 
provide only marginal benefit 
for nondiabetic kidney disease 
& no benefit in diabetic renal 
disease  
 
When analysis was limited to 
studies with no BP difference, 
no benefit was identified 
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ABCD trial 
(Appropriate 
Blood Pressure 
Control Trial)  
Patients with 
microalbumin
uria & mean 
baseline GFR 
84 ml/min 
Comparison of 
ACEI & CCB  
No difference in renal outcome 
when BP lowered < 130/80 
mmHg 
 
Table 2. B. Summary of Trials in patients with renal disease and renal outcomes (Renal 
Trials). DIABETIC 
4. Cardiovascular trials 
While it has been suggested that ACEI/ARBs are beneficial in individuals with 
cardiovascular disease, it is the achieved blood pressure rather than the specific drug that 
may be responsible for the benefits. Also, while the JNC 7 recommends a target blood 
pressure of less than 140/90, the data cited below also suggest that as in CKD (chronic 
kidney disease), a blood pressure target of less than 130/80 may be appropriate. 
In the HOPE Trial (Heart Outcomes Prevention Evaluation) (57,58) patients with high 
cardiovascular risk (without acute MI, LV dysfunction or heart failure) were randomly 
assigned to Ramipril 5-10 mg/day or placebo. The trial was terminated prematurely after 
4.5 years because of significant benefits in the Ramipril arm with only14% reaching the 
primary end point (any cardiovascular event: CVA, MI, Cardiovascular death) versus 17.8 
percent in the placebo group. A reduction was also seen in stroke events despite a mean BP 
of 135/76, which was only 3.3/1.4 mm Hg less than placebo (59). However, although the 
benefits were thought to be independent of BP control, an analysis of a subset of 38 patients 
who underwent ambulatory blood pressure monitoring showed a significant drop in night 
time blood pressure. 
The EUROPA Trial (European Trial on Reduction of cardiac Events with Perindopril in 
Stable Coronary Artery Disease) was similar to the HOPE but patients in this trial had 
lower cardiovascular risk as evidenced by lower prevalence of hypertension, diabetes or 
peripheral vascular disease as well as lower cardiovascular mortality in the placebo 
group. The mean blood pressure at entry was 137/82 mm Hg. In this study patients were 
given Perindopril (8 mg once a day) or placebo and were followed for a mean of 4.2 years 
with primary end point of MI, cardiac arrest or cardiovascular death. A significant 
reduction in primary end point was noted in favour of the Perindopril group vs. Placebo 
(8 versus 10). However Perindopril therapy was associated with a blood pressure that was 
5/2 mm Hg lower than placebo (60). Hence from both of these trials it can be concluded 
that the benefits of ACEI may be due to lowering of blood pressure and not to intrinsic 
property of the ACEI. 
The two trials comparing ACEIs and CCBs were the VALUE and CAMELOT Trials.  
The VALUE Trial (Valsartan Antihypertensive Long–term use evaluation) evaluated 
Valsartan versus Amlodipine in 15,000 hypertensive patients with mean blood pressure 
155/88 mm Hg. Initial findings noted fewer Myocardial Infarctions and strokes within the 
Amlodipine arm, however further analysis showed significant differences in blood 
pressure in favour of Amlodipine group. The structure of the trial was so designed to 
gradually introduce diuretics in the Valsartan arm over several months. Until this was 
achieved, a higher blood pressure in the Valsartan group produced higher event rates that 
subsequently disappeared as blood pressure control improved. A post hoc attempt to 
control for this difference with matched blood pressure pairings of Amlodipine and 
Valsartan groups showed no difference in cardiac events, MI, stroke or mortality (61). 
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This study once again suggested that the main determinant of cardiovascular event was 
blood pressure response. 
The CAMELOT Trial (Comparison of Enalapril vs. Amlodipine to Limit Occurrences of 
Thrombosis) compared Amlodipine (10 mg per day) and Enalapril (20 mg per day) versus 
placebo in reducing cardiovascular endpoints in patients with known coronary disease 
(62). The main outcomes were non-fatal MI, cardiac arrest and other cardiovascular 
events, which occurred at a rate of 23 % in placebo, 16.6% in Amlodipine and 20.2 % in the 
Enalapril group. Blood pressure increased by 0.7/0.6 mm Hg in placebo group and 
decreased by 4.8/2.5 mm Hg and 4.9/2.4 mm Hg in the Amlodipine and Enalapril groups 
respectively. Though there were equivalent hard endpoint events (all-cause mortality, non 
fatal MI, stroke) in both Amlodipine and Enalaprilarms, the soft endpoint events such as 
angina pectoris were significantly reduced by Amlodipine, hence reducing the total in 
favour of Amlodipine. While Amlodipine is known to have anti-anginal effect it is not the 
case with Enalapril. Also there were differences in pharmacodynamics of the drugs as 
Enalapril once a day has a half life of 11 hours while that of Amlodipine is 50 hours. 
Hence, since Enalapril was taken in the mornings, the blood pressure readings during the 
day will have severely underestimated the rise in night time BP in the Enalapril arm 
compared to Amlodipine. 
The role of CCBs in patients with high cardiovascular risk was further evaluated in the four 
trials outlined below. The INSIGHT Trial (Intervention as a Goal in Hypertension 
Treatment) of 6000 high risk patients defined as having Hypertension plus at least one 
additional cardiovascular risk factor, compared CCB (Nifedipine) to Hydrochlorothiazide 
plus Amiloride (63). In this study total cardiovascular outcome (cardiovascular death, 
myocardial infarction, congestive heart failure, stroke) were the same in both groups, 
however the Nifedipine arm showed higher risk of fatal myocardial infarction and non fatal 
heart failure.  
The INVEST Trial (The International verapamil-Trandolapril Study Hypertensive 
patients with known coronary artery disease compared Verapamil (maximum dose 180 
mg twice daily) and Atenolol (maximum dose 50 mg twice daily) in reducing 
cardiovascular mortality and morbidity. Trandanopril and/or Thiazides were added for 
additional blood pressure control as needed. There was no difference in primary 
outcomes of death, non fatal myocardial infarction or nonfatal stroke (64). Hence, while 
DHP-CCBs (Nifedipine) were shown to increase cardiovascular mortality, non DHP-CCBs 
(Verapamil) have not shown such adverse outcomes. It has been shown that the peak and 
trough concentrations and variability in blood pressure with short acting Nifedipineare 
likely responsible factors for the increased cardiovascular mortality. This was further 
evaluated by the ACTION Trial (A Coronary Disease Trial Investigating Outcomes with 
Nifedipine GITS) comparing long acting Nifedipine (60 mg once a day) to placebo in 
patients with chronic stable angina (65). Most patients were treated with other anti-
anginal therapy including Beta-blockers, aspirin and lipid lowering drugs and had a mean 
BP of 137/80.The primary end point was survival free of major cardiovascular events. At 
a follow up of 4.9 years, the mean blood pressure was significantly lower in the long 
acting Nifedipine group however despite this, it did not reduce primary end points or all 
cause mortality. The lack of benefit despite lowering of blood pressure may be due to 
lower cardiovascular risk of the patient population studied.  
The ASCOT Trial (The Anglo-Scandinavian Cardiac Outcomes Trial) was designed to 
compare the incidence of adverse cardiovascular outcomes with Amlodipine 5 mg versus 
www.intechopen.com
 
Chronic Kidney Disease and Renal Transplantation 136 
Atenolol 50 mg in patients with hypertension and at least three other risk factors for 
Coronary Heart Disease. The combined primary outcome was fatal coronary events and 
nonfatal MI. Surprisingly, the trial was stopped prematurely due to worse outcomes in the 
Atenolol treated group (66, 67). Possible reasons for the difference in outcomes include 
lower blood pressure in Amlodipine group as well as once daily usage of Atenolol despite 
pharmokinetics favouring twice daily use as in the INVEST trial. It was estimated that the 
difference in blood pressure accounts for at least half the variance in outcomes. Therefore in 
summary, the ASCOT trial which included patients with no active cardiovascular disease, 
there was a difference in outcomes between Amlodipine and Atenolol partially attributed to 
BP differences between the two groups. In INVEST trial no such difference was observed 
though it was in a different population. 
In the NAVIGATOR Trial (Valsartan in Impaired Glucose Tolerance Outcomes Research) 
in patients with Impaired Glucose Tolerance, over 9300 patients who had or were at risk of 
cardiovascular disease were randomly assigned to Valsartan (up to 160 mg/day) or placebo 
(68). The mean baseline BP was 140/83 mm Hg in both arms. At a median of 6.5 years there 
was no difference in the rate of cardiovascular events, despite significant lower blood 
pressure with Valsartan (132/78 mm HG, 2.8/1.4 mm Hg lower than placebo). 
In the ACCORD BP Trial (Action to Control Cardiovascular Risk in Diabetes) of Goal 
Systolic Pressure less than 120 mm Hg in Type 2 Diabetes, 4733 patients were randomly 
assigned to a goal systolic blood pressure of less than 120 or less than 140 mm Hg (69). 
The mean baseline BP was 139/76 mm Hg at year one and thereafter, the average systolic 
pressures were 119 and 134 mm Hg in the two groups. At a mean follow up of 4.7 years, 
there was no significant difference between the groups in the primary outcome of 
cardiovascular death or non-fatal MI or stroke (1.9 versus 2.1 percent). The annual rate of 
all cause mortality was non-significantly higher with intensive therapy (1.28 versus 1.19 
percent). Serious adverse events occurred in a higher proportion (3.3 versus 1.3 percent) 
in the intensive therapy arm. However, a prespecified secondary outcome, the annual rate 
of stroke, was significantly lower with intensive therapy (0.32 versus 0.53 percent). The 
conclusion of the ACCORD Trial, for those who meet the entry criteria (type 2 Diabetes 
Mellitus plus either cardiovascular disease or at least two additional risk factors for 
cardiovascular disease), the authors and reviewers of this topic suggest that the risks and 
burdens of aiming for a systolic pressure of less than 120 mm Hg plus the lack of 
experience of almost all physicians in attaining such a goal may be too great a burden to 
achieve the small reduction in stroke that may be attained (absolute benefit 1 in 89 
patients at five years). 
The ONTARGET Trial randomly assigned over 25,000 patients with atherosclerotic disease 
to Ramipril, Temlisartan, or both (54). There was a progressive reduction in stroke risk at 
attained systolic pressures of 121 compared to 130 mmHg or higher; in contrast, there was 
an increase in myocardial infarction risk at attained systolic pressures below 126 mmHg and 
cardiovascular mortality was unchanged or increased at attained systolic pressures below 
130 mmHg expand. 
The PROGRESS Trial (Preventing Strokes by Lowering Blood Pressure in patients with 
Cerebral Ischemia) compared Perindopril with or without adding Indapamide (a thiazide 
diuretic) to placebo in patients with a prior stroke (70). There was a progressive trend 
toward lower rates of recurrent stroke at lower systolic pressures down to below 120 mmHg 
in Perindopril group as compared to placebo. However as this was a placebo controlled trial 
the benefits of a particular anti hypertensive group of drugs were not studied. 
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Trials Population 
Studied 
Intervention Outcome Comments 
HOPE Trial 
(Heart Outcomes 
Prevention 
Evaluation)  
Patients with 
high 
cardiovascular 
risk (without 
acute MI, LV 
dysfunction or 
heart failure) 
Randomly assigned 
to Ramipril 5-10 
mg/day or placebo 
Terminated prematurely 
because of significant 
benefits in Ramipril arm  
only14% reaching primary 
end point (any 
cardiovascular event: CVA, 
MI, Cardiovascular death) 
vs17.8% in placebo 
 
A reduction in stroke was 
also seen with Ramipril 
Although benefits 
were thought to be 
independent of BP 
control, an analysis 
of subset who 
underwent ABPM 
showed a significant 
drop in night time 
BP 
EUROPA Trial 
(European Trial 
on Reduction of 
cardiac Events 
with Perindopril 
in Stable 
Coronary Artery 
Disease) 
Similar to 
HOPE but 
patients with 
lower 
cardiovascular 
risk 
Perindopril (8 mg 
once a day) vs 
placebo  
 
 
Primary end point: MI, 
cardiac arrest or 
cardiovascular death- 
significant reduction in 
favour of Perindopril  
Perindopril associated with 
(5/2 mmHg) lower BP  
Benefits of ACEI 
may be due to BP 
lowering and not to 
intrinsic property of 
the ACEI 
 
VALUE Trial 
(Valsartan 
Antihypertensive 
Long –term use 
evaluation) 
 15,000 
hypertensive 
patients 
Valsartan vs 
Amlodipine 
Initial findings fewer 
Myocardial Infarctions and 
strokes in Amlodipine arm, 
however there were 
significant differences in BP 
in favour of Amlodipine 
  
A post hoc attempt to 
control for this difference 
with matched BP pairings of 
Amlodipine and Valsartan 
groups showed no 
difference in cardiac events, 
MI, stroke or mortality 
Suggests that main 
Determinant of 
cardiovascular event 
is BP response 
CAMELOT Trial 
(Comparison of 
Enalapril vs. 
Amlodipine to 
Limit Occurrences 
of Thrombosis) 
Patients with 
known 
coronary 
disease 
Compared 
Amlodipine (10 
mg per day) and 
Enalapril (20 mg 
per day) vs 
placebo in 
reducing 
cardiovascular 
endpoints 
Equivalent hard endpoint 
events (all-cause mortality, 
non fatal MI, stroke) in both 
Amlodipine and Enalapril 
arms 
 
Soft endpoint events such as 
angina pectoris were 
significantly reduced by 
Amlodipine, hence reducing 
the total in favour of 
Amlodipine 
 Amlodipine has 
anti-anginal 
properties 
 
Differences exist in 
pharmacodynamics 
of the drugs 
(Enalapril half life 
shorter than 
Amlodipine 11 vs 50 
hrs) 
The INSIGHT 
Trial 
(Intervention as a 
Goal in 
6000 high risk 
patients 
defined as 
having 
CCB (Nifedipine) 
to 
Hydrochlorothiazi
de plus Amiloride 
Cardiovascular outcome 
(cardiovascular death, 
myocardial infarction, 
congestive heart failure, 
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Hypertension 
Treatment) 
Hypertension 
plus at least 
one additional 
cardiovascular 
risk factor 
stroke) were same 
 
However Nifedipine arm 
showed higher risk of fatal 
myocardial infarction & non 
fatal heart failure 
The INVEST 
Trial (The 
International 
verapamil- 
Trandolapril 
Study) 
Hypertensive 
patients with 
known 
coronary artery 
disease 
Compared 
Verapamil and 
Atenolol in 
reducing 
cardiovascular 
mortality & 
morbidity  
Trandanopril 
and/or Thiazides 
added for BP 
control as needed 
No difference in primary 
outcomes of death, non fatal 
myocardial infarction or 
nonfatal stroke 
 
 
In contrast to 
outcomes with 
Nifedipine 
suggesting that peak 
/ trough 
concentrations and 
variability in BP with 
short acting 
Nifedipine might be 
responsible for 
increased 
cardiovascular 
mortality 
ACTION Trial (A 
Coronary Disease 
Trial 
Investigating 
Outcomes with 
Nifedipine GITS) 
Patients with 
chronic stable 
angina 
long acting 
Nifedipine (60 mg 
once a day) vs 
placebo  
Primary end point: survival 
free of major cardiovascular 
events  
Mean BP significantly lower 
in long acting Nifedipine 
group however despite this, 
it did not reduce primary 
end points or all cause 
mortality 
May be due to lower 
cardiovascular risk of 
the patients 
 
ASCOT Trial 
(The Anglo- 
Scandinavian 
Cardiac 
Outcomes Trial) 
Patients with 
hypertension 
and at least 
three other risk 
factors for 
Coronary 
Heart Disease 
Amlodipine 5 mg 
vs Atenolol 50 mg 
Primary outcome: fatal 
coronary events and 
nonfatal MI  
 
Stopped prematurely due to 
worse outcomes in Atenolol 
group 
Reasons for 
difference in 
outcomes include 
lower BP in 
Amlodipine group 
and once daily usage 
of Atenolol despite 
pharmokinetics 
favouring twice 
daily use 
NAVIGATOR 
Trial (Valsartan 
in Impaired 
Glucose 
Tolerance 
Outcomes 
Research 
Over 9300 
patients with 
Impaired 
Glucose 
Tolerance at 
risk of 
cardiovascular 
disease 
Randomly 
assigned to 
Valsartan or 
placebo  
No difference in rate of 
cardiovascular events, 
despite significant lower BP 
with Valsartan 
 
ACCORD BP 
Trial (Action to 
Control 
Cardiovascular 
Risk in Diabetes) 
4733 patients 
type 2 Diabetes 
Mellitus plus 
either 
cardiovascular 
Randomly assigned 
to goal systolic BP 
< 120 vs <140 mm 
Hg  
No significant difference in 
primary outcome of 
cardiovascular death or non-
fatal MI or stroke  
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disease or at 
least two 
additional risk 
factors  
All cause mortality was non-
significantly higher with 
intensive therapy 
 
Higher rate of serious 
adverse events in intensive 
therapy arm but secondary 
outcome: annual stroke rate 
was significantly lower 
ONTARGET 
Trial 
Over 25,000 
patients with 
atherosclerotic 
disease 
Randomly 
assigned to 
Ramipril, 
Temlisartan, or 
both 
 
 
Reduction in stroke risk at 
systolic BP 121 vs 130 
mmHg or higher 
 
An increase in myocardial 
infarction risk at systolic BP 
< 126 mmHg  
 
Cardiovascular mortality 
unchanged or increased at 
systolic BP < 130 mmHg 
 
PROGRESS Trial 
(Preventing 
Strokes by 
Lowering Blood 
Pressure in 
patients with 
Cerebral 
Ischemia) 
Patients with a 
prior stroke 
Perindopril with or 
without 
Indapamide (thiazi
de diuretic) vs 
placebo 
 
Trend toward lower rates of 
recurrent stroke at lower 
systolic BP (down to < 120 
mmHg) in Perindopril 
group  
 
As this was placebo 
controlled trial, 
benefits of a 
particular anti 
hypertensive group 
of drugs were not 
studied 
Table 3. Summary of Cardiovascular Trials 
“Reconciling the evidence” 
Some controversies still exist in hypertension trials. For example, though it is established 
unequivocally that hypertension is a risk factor for chronic kidney disease and cardiovascular 
disease, the superiority of individual drug classes over others, with regards to these outcomes 
remains unclear. Landmark trials, such as the ALLHAT (Antihypertensive and Lipid 
Lowering to Prevent Heart Attack Trial) (6) lie at the heart of this controversy. Their finding of 
no superiority for Angiotensin converting enzyme inhibitors (ACEI) with respect to ESRD 
outcome is in clear contradiction to the multitude of outcome trials in CKD patients where the 
role of ACEI has been established. 
Further confusion in comparing outcomes from various trials arises because of variability in 
their design, patient demographics, underlying cardiovascular risk factors as well as the 
studied primary outcomes. This leads to tremendous variability in studies addressing the 
supremacy or lack of, for a specific drug class. For instance, the LIFE trial (Lorsartan 
Intervention for End Points) (71) demonstrated lower CV outcomes for patients with LVH 
treated with Losartan versus Atenolol despite equivalent blood pressure (BP) control. 
Conversely, in VALUE (Valsartan Antihypertensive Long Term Use Evaluation)(72) 
Valsartan did not show benefit in cardiovascular mortality as compared to Amlodipine for 
the same level of blood pressure control. However, there was significant difference in the 
blood pressure between the two groups favouring the Amlodipine arm. These studies show 
www.intechopen.com
 
Chronic Kidney Disease and Renal Transplantation 140 
how the conduct of different trials can lead to contrasting findings with respect to 
superiority of one drug over the other and the care needed to evaluate them. 
Controversies further arise when trials designed to study cardiac outcomes are used to 
evaluate renal outcomes. One example is the ALLHAT trial (6), which showed that diuretics 
were superior to ACEI with regards to renal outcomes, even though it was primarily 
designed to study cardiac and not renal outcomes. This is in contrast to most studies with 
primary renal outcomes which showed that administration of ACEI or Angiotensin receptor 
blockers (ARBs) was associated with lower urine protein excretion, slower doubling of 
serum creatinine and lower rate of decline of GFR and hence progression to End Stage Renal 
Disease (ESRD). However these renal outcome trials were not designed or powered to 
evaluate cardiovascular events. Therefore it is important to carefully scrutinize trials to 
identify the primary outcome they were intended to and thus are powered to assess. 
Possible explanations for the adverse outcomes seen with ACEI in ALLHAT include the 
following: 
The diuretic arm had better control of blood pressure. During The first two years there was 
a significantly better BP control of at least 4 mm Hg in the diuretic arm. 
The ACEI may be handicapped by the unfavourable use of Beta-blockers as add- on therapy 
in a significant number of black patients.  
In the ALLHAT trial Beta-blockers were used as a second line agent in all four groups. 
Specifically, only 18 percent of the ACEI group received a diuretic and mainly in the last 
year or two. This led to a 4-5 mm Hg higher blood pressure in the ACEI arm likely 
accounting for greater CV outcomes. 
The ALLHAT trial hence concluded that diuretics are similar if not superior to ACEI and 
CCBs with regards to cardiovascular protection and mortality. However the increased 
incidence of diabetes mellitus noted with diuretic use is not without significant clinical 
consequences. Notably, the effect of diabetes on CV event rates is not apparent until a 
minimum of 6 years and becomes progressively more pronounced. It eventually results in 
increased cardiovascular event rate at 15 years, which is similar to that seen in pre-existing 
diabetes. This was shown in SHEP trial (Systolic Hypertension in Elderly Program) where 
new onset diabetes was associated with a high risk of CV events, similar to its incidence in 
patients with diabetes at the beginning of the study (73). Hence, because of the short 
observation period of ALLHAT of only 12.5 years, diuretic-linked new onset diabetes, 
would be expected to result in increased CV events had the follow- up been extended. 
Possible explanations for the contrasting findings between the ALLHAT and ANBP2 trials 
include: 
1. Different patient demographics, with a predominant white population as compared to 
high proportion of black patients in ALLHAT trial who were in fact older. As stated 
previously white patients have shown better response to ACEI’s than diuretics. 
2. The patient population were different, ALLHAT included patients with one additional 
cardiovascular risk factor. 
3. In ANBP2 trial the antihypertensive agent (Lisinopril or Hydrochlorothiazide) and dose 
were chosen by the physician. The possible high dose use of Hydrochlorothiazide with its 
associated adverse cardiovascular side effects may have contributed to adverse outcomes. 
4. Primary outcomes for ALLHAT and ANBP2 were different. While in ALLHAT the 
primary outcome was death from coronary causes or nonfatal myocardial infarction, in 
ANBP2 it was all fatal and nonfatal cardiovascular events. Once again this highlights 
how differences between ALLHAT and ANBP2 trials in design, demographics and 
outcomes can influence the results of the study. 
www.intechopen.com
 
Recent Trials in Hypertension 141 
Though, the ALLHAT Trial (24) of more than 44,000 hypertensive patients failed to show 
superiority of ACEI, DHP-CCBs and alpha blockers over a thiazide diuretic with respect to 
cardiovascular outcomes. In post hoc analysis, neither ACEI nor CCB was superior to thiazide 
diuretic with respect to renal outcomes. This trial was contradictory to other primary renal 
outcome trials that showed benefit of ACEI over other drug classes. Some of the factors 
responsible for this controversy will be explored. The ALLHAT did not select patients with 
renal disease as an inclusion criterion, since it was not mainly a renal outcome trial. Blood 
pressure was also lower in thiazide arm as compared to the other arms hence equivalency of 
blood pressure was not achieved. Furthermore, no urine tests were performed even though 
renal outcomes were studied thus failing to identify those who were at highest risk for 
progression and most likely to derive benefit from ACEI i.e. patients with proteinuric diabetic 
kidney disease. Hence, in the ALLHAT trial little or no attention was paid to kidney function, 
consequently the results of ALLHAT regarding renal outcomes remain unresolved. 
In addition, the Casas meta-analysis was heavily weighted on the ALLHAT (non renal 
outcome trial) and little or no attention was paid to IDNT, RENAAL, AASK and REIN trials, 
the latter studies upon which our current guidelines are based. Hence, this analysis correctly 
concludes that these agents benefit non-diabetic renal disease and, mistakenly deduces that 
ACEI/A2RBs are non beneficial in diabetic proteinuric kidney disease. This partially flawed 
trial may result in physicians using less effective antihypertensive drugs in patients with 
kidney disease. Any attempt to reconcile the renal outcomes in ALLHAT, a cardiovascular 
outcomes trial, with those from IDNT, RENAAL, REIN, AASK and other renal trials fails 
because of different patient populations, designs and outcomes. Though less expensive 
antihypertensive drugs are desirable for BP control, they are less effective for renoprotection 
in chronic kidney disease and should therefore be used as adjuncts. Moreover, the average 
GFR of the studies selected was equivalent to Stage 2 CKD, and was much higher than in 
those studies that showed benefit of ACEI and ARBs. 
Clinical pearls 
It can be concluded that ACEIs are the medication of choice in reducing microalbuminuria 
in diabetic hypertensive patients. Studies clearly show that blocking of the Renin 
Angiotensin Aldosterone System (RAAS) with ACEI or ARBs in patient with type II 
diabetes mellitus reduces the risk of progression of microalbuminuria to overt proteinuria 
and may even revert it back to normoalbuminuria, both in hypertensive and normotensive 
patients. It is also likely that Aliskerin may have additional renoprotective effects, 
independent of blood pressure lowering, in hypertensive patients with type2 diabetes and 
nephropathy who are already receiving the recommended therapy. 
Recommendations on choice of antihypertensive agents 
The choice of antihypertensive agents in diabetic patients is based upon their ability to 
prevent adverse cardiovascular events and to slow progression of renal disease, if present.  
The two major studies which would influence the choice of therapy are the ALLHAT and 
ACCOMPLISH trials. To summarize again, in the ALLHAT trial, the benefits from diuretics 
compared to other classes, may have been related to the lower attained blood pressures. 
Another factor which was not addressed was the detrimental effects of thiazides on glucose 
metabolism. In the ACCOMPLISH trial, on the other hand, the combination of an ACE 
inhibitor and CCB provided better cardiovascular protection as compared to ACE inhibitor 
with thiazide.  
While long acting ACEI or ARB would be the drug of choice in diabetic patients with 
hypertension and microalbuminuria, we would also recommend adding a long acting 
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dihydropyridine calcium channel blocker as combination therapy for uncontrolled 
hypertension, given the results of ACCOMPLISH trial. If a Beta-blocker is given, 
Carvedilol may be the drug of choice because of potential benefits on glycemic control and 
lower rate of development of microalbuminuria compared to Metoprolol. A loop diuretic is 
likely to be necessary in patients with renal disease or heart failure. 
Recommendations on target/goal blood pressure 
Based on the trials described above including ACCORD BP trial, we recommend, a goal blood 
pressure of less than 140/90 mmHg in patients with diabetes. A goal blood pressure of less 
than 130/80 mmHg is recommended for patients with diabetic nephropathy and proteinuria 
(defined as 500 mg/day or more). These recommendations differ from the pre-ACCORD era 
when a goal of less than 130/80 mmHg was recommended for all diabetic patients.  
Goal BP recommendations 
While the guidelines suggested by European Society of Hypertension/European Society of 
Cardiology and American Heart Association recommend a blood pressure less than 130/80 
for patients with atherosclerotic cardiovascular disease, the recent ACCORD trial along with 
ONTARGET and PROGRESS raise some concerns with this target.  
We recommend antihypertensive therapy to lower the blood pressure to less than 140/90 
mmHg in all patients. An attempt to lower the systolic pressure below 130 to 135 mmHg 
should be undertaken, if it can be achieved without producing significant side effects, though 
this has not been well defined. The risks of aiming for a goal systolic pressure of less than 120 
mmHg may be too great a burden to achieve the small reduction in stroke that may be attained 
(absolute benefit 1 in 89 patients at five years). However, such a goal may be considered in 
highly motivated patients who would accept more aggressive antihypertensive therapy to 
further reduce their risk of stroke.  
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